All In Biotech

Drug Trial Radar · NCT01220622

Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes

Nimodipine Preventing Cognitive Impairment in Ischemic Cerebrovascular Events: A Randomized, Placebo-Controlled, Double-Blind Trial (NICE)

Last checked: Nov 19, 2026Latest source record: Oct 14, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 656 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

656

Planned (sponsor's estimate)

Start

Oct 2010

Primary completion

Apr 2012

Study completion Jul 2012

Sponsor

Sponsor type
Government (non-federal)
First posted
Oct 14, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 30 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial was designed to test the hypothesis that early treatment with nimodipine has a positive effect on cognition impairment after acute ischemic stroke.

Conditions

  • Stroke
  • Mild Cognitive Impairment

Interventions

  • NimodipineDrug

    Administration of nimodipine 30mg tid for 6 months

  • PlaceboDrug

    Administration of placebo 30mg tid for 6 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess the effect of nimodipine on the cognitive function after acute cerebral ischemia with ADAS-cog and MMSE at 6 months in the ITT populationTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tian Tan Hospital, Capital Medical University

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.